Circulating Insulin-like Growth Factor-1 and Insulin-like Growth Factor Binding Protein-3 predict Three-months Outcome after Ischemic Stroke
| Autor: | Moritz Armbrust, Reinhard Dengler, Martin Ebinger, Matthias Endres, Ralf Lichtinghagen, Christoph C. Eschenfelder, Helmut Schumacher, Hans Worthmann |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Gastroenterology Disease-Free Survival Insulin-like growth factor-binding protein Brain Ischemia law.invention 03 medical and health sciences Insulin-like growth factor 0302 clinical medicine Endocrinology Randomized controlled trial law Modified Rankin Scale Internal medicine Internal Medicine Humans Medicine Insulin-Like Growth Factor I Survival rate Stroke Aged biology business.industry Confounding General Medicine Heparin Middle Aged medicine.disease Surgery Survival Rate Insulin-Like Growth Factor Binding Protein 3 biology.protein Female business Biomarkers 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Experimental and Clinical Endocrinology & Diabetes. 125:485-491 |
| ISSN: | 1439-3646 0947-7349 |
| Popis: | Reports on neuroprotective effects of Insulin-like growth factor-1 (IGF-1) and Insulin-like growth factor binding protein-3 (IGFBP-3) in ischemic brain tissue are inconsistent. The aim of this study was to determine if plasma levels of IGF-1 and IGFBP-3 in acute stroke patients are indicative of 3 months functional outcome. Plasma levels were measured via chemiluminescence immunoassay in heparin blood samples of patients included in the EARLY trial (NCT00562588). Plasma samples were drawn on admission and 8 days post-stroke. Neurological deficits were assessed via modified Rankin Scale (mRS) 3 months post-stroke, resulting in favorable (mRS=0–2) or unfavorable (mRS=3–6) outcome. A multiple binary logistic regression including IGF-1 and IGFBP-3 levels and confounders was conducted. Out of 404 included patients, 89 patients had an unfavorable outcome. Mean mRS on admission as well as 3 months post-stroke was 2 (±1). Low IGF-1 levels (day 8) were independently associated with a decreased risk of an unfavorable outcome (OR 0.61; 95%CI 0.37–0.99; p=0.044). Low IGFBP-3 levels (day 8) were independently associated with an unfavorable outcome (OR 2.75; 95%CI 1.56–4.84; p Low IGFBP-3 levels and high IGF-1 levels in the subacute phase are predictive of unfavorable outcome 3 months after stroke. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|